Express News | U.S.-Listed Chinese Stocks Surge in Overnight Trading Following Politburo's Commitment to Fiscal Support
US Listed-Chinese Stocks Surge Tuesday on Policy Boost, Who Is Leading the Way
Express News | U.S.-Listed Shares of Chinese Firms Jump Premarket After China Announces Stimulus Measures
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring Presents Efficacy/Safety Results From a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
Express News | Beyondspring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During Esmo Congress 2024 Showcasing Its Lead Anti-Cancer Asset, Plinabulin
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
BeyondSpring Inc. Reports Mid-Year Financials
Express News | Beyondspring-After Series a-3 Financing 1St Close, Co, Seed Technology Limited to Own About 46.9% of Outstanding Equity Interest in Seedtherapeutics
Express News | Beyondspring Inc - Seed to File Ind for Tau Degrader Program in 2026
Express News | Seed Therapeutics Announces $1.5B Research Collaboration With Eisai
Express News | Seed Therapeutics (Seed) Enters Into Strategic Research Collaboration With Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
BeyondSpring Raises $3 Million via Stock Sale
Express News | Beyondspring Inc Files for Stock Shelf Offering of up to 10 Mln Ordinary Shares- SEC Filing
BeyondSpring (NASDAQ:BYSI) Shareholders Have Earned a 141% Return Over the Last Year
Express News | BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics
Express News | BeyondSpring Reports FY23 Loss Per Share Of $(0.54) Vs. $(0.85) Last Year
Press Release: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results